Cited 6 times in
Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이주용 | - |
dc.contributor.author | 조강수 | - |
dc.contributor.author | 문영준 | - |
dc.contributor.author | 정재용 | - |
dc.date.accessioned | 2022-12-22T04:16:41Z | - |
dc.date.available | 2022-12-22T04:16:41Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192088 | - |
dc.description.abstract | Purpose: During the coronavirus disease 2019 (COVID-19) pandemic, the European Association of Urology (EAU) recommended that courses of intravesical bacillus Calmette-Guérin (BCG) therapy lasting more than 1 year could be safely terminated for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). Thus, we conducted a systematic review and network meta-analysis according to EAU's COVID-19 recommendations. Materials and methods: A systematic review was performed following the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. We conducted a network meta-analysis of recurrence rate in patients with NMIBC receiving induction therapy (M0) and those receiving maintenance therapy lasting 1 year (M1) and more than 1 year (M2). Results: Nineteen studies of 3,957 patients were included for the network meta-analysis. In a node-split forest plot using Bayesian Markov Chain Monte Carlo (MCMC) modeling, there were no differences between the M1 and M2 groups in recurrence rate [odds ratio (OR) 0.95 (0.73-1.2)]. However, recurrence rate in the M0 group was higher than that in the M1 [OR 1.9 (1.5-2.5)] and M2 [OR 2.0 (1.7-2.4)] groups. P-score tests using frequentist inference to rank the treatments in the network demonstrated that the therapy used in the M2 group (P-score 0.8701) was superior to that used in the M1 (P-score 0.6299) and M0 groups (P-score 0). In rank-probability tests using MCMC modeling, the M2 group showed the highest rank, followed by the M1 and M0 groups. Conclusion: In the network meta-analysis, there were no differences between those receiving BCG maintenance therapies in terms of recurrence rate. In the rank tests, therapy lasting more than 1-year appears to be most effective. During the COVID-19 pandemic, 1-year maintenance therapy can be used, but after the COVID-19 pandemic, therapy lasting more than 1-year could be beneficial. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Public Library of Science | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adjuvants, Immunologic | - |
dc.subject.MESH | Administration, Intravesical | - |
dc.subject.MESH | BCG Vaccine / therapeutic use | - |
dc.subject.MESH | Bayes Theorem | - |
dc.subject.MESH | COVID-19* | - |
dc.subject.MESH | Duration of Therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Mycobacterium bovis* | - |
dc.subject.MESH | Neoplasm Invasiveness | - |
dc.subject.MESH | Neoplasm Recurrence, Local / drug therapy | - |
dc.subject.MESH | Network Meta-Analysis | - |
dc.subject.MESH | Pandemics | - |
dc.subject.MESH | Urinary Bladder Neoplasms* / drug therapy | - |
dc.subject.MESH | Urology* | - |
dc.title | Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Young Joon Moon | - |
dc.contributor.googleauthor | Kang Su Cho | - |
dc.contributor.googleauthor | Jae Yong Jeong | - |
dc.contributor.googleauthor | Doo Yong Chung | - |
dc.contributor.googleauthor | Dong Hyuk Kang | - |
dc.contributor.googleauthor | Hae Do Jung | - |
dc.contributor.googleauthor | Joo Yong Lee | - |
dc.identifier.doi | 10.1371/journal.pone.0273733 | - |
dc.contributor.localId | A03161 | - |
dc.contributor.localId | A03801 | - |
dc.contributor.localId | A06283 | - |
dc.relation.journalcode | J02540 | - |
dc.identifier.eissn | 1932-6203 | - |
dc.identifier.pmid | 36074771 | - |
dc.contributor.alternativeName | Lee, Joo Yong | - |
dc.contributor.affiliatedAuthor | 이주용 | - |
dc.contributor.affiliatedAuthor | 조강수 | - |
dc.contributor.affiliatedAuthor | 문영준 | - |
dc.citation.volume | 17 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | e0273733 | - |
dc.identifier.bibliographicCitation | PLOS ONE, Vol.17(9) : e0273733, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.